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Robust biomarkers that can precisely stratify patients according to treatment needs are
in great demand. The literature is inconclusive for most reported prognostic markers
for colorectal cancer (CRC). Hence, adequately reported studies in large representative
series are necessary to determine their clinical potential. We investigated the prognos-
tic value of three Wnt signaling-associated proteins, β-catenin, E-cadherin, and SOX9, in
a population-representative single-hospital series of 1290 Norwegian CRC patients by
performing immunohistochemical analyses of each marker using the tissue microarray
technology. Loss of membranous or cytosolic β-catenin and loss of cytosolic E-cadherin pro-
tein expression were significantly associated with reduced 5-year survival in 903 patients
who underwent major resection (722 evaluable tissue cores) independently of standard
clinicopathological high-risk parameters. Pre-specified subgroup analyses demonstrated
particular effect for stage IV patients for β-catenin membrane staining (P = 0.018; for-
mal interaction test P =0.025). Among those who underwent complete resection (714
patients, 568 evaluable), 5-year time-to-recurrence analyses were performed, and stage II
patients with loss of cytosolic E-cadherin were identified as an independent high-risk sub-
group (P =0.020, formal interaction test was not significant). Nuclear β-catenin and SOX9
protein, regardless of intracellular location, were not associated with prognosis. In con-
clusion, the protein expression level of membranous or cytosolic β-catenin and E-cadherin
predicts CRC patient subgroups with inferior prognosis.
Keywords: beta-catenin, E-cadherin, SOX9 transcription factor, prognostic biomarkers, colorectal cancer, biomarker
discovery, guideline adherence
INTRODUCTION
As of 2008, 1.2 million patients were diagnosed with col-
orectal cancer (CRC) annually, and only about half of them
were alive 5 years after their initial diagnosis (1). Clinicopatho-
logical staging is the best available system to predict disease
course, however, the system offers only crude estimates lead-
ing to unnecessary treatment of a large number of patients on
one hand, and recurrence of disease among patients who only
received surgery, on the other hand. Taken together with the fact
that CRC risk increases with age and that the world’s popula-
tion is both growing and aging, the coming decades will put
an unprecedented pressure on health care institutions world-
wide (2). Therefore, the need for molecular biomarkers to guide
clinical decision-makers on how to stratify patients into opti-
mal treatment regiments has never been greater. In particular,
patients with stage II CRC are not routinely offered adjuvant
therapy, although about 20–30% of them experience relapse
and die within 5 years after surgery (3). Also, stage III patients
above 75 years of age are not routinely offered adjuvant ther-
apy although evidence suggests a benefit from such treatment
(4, 5). Prognostic biomarkers that distinguish between both
high-risk and low-risk patients within these stages are highly
warranted.
In the early 90s, the hereditary cancer syndrome familial ade-
nomatous polyposis (FAP) was discovered to be directly linked
to mutations within the adenomatous polyposis coli gene (APC)
(6, 7). Two years later, a close interaction between APC and β-
catenin was demonstrated (8, 9), and as APC mutations were
found at high frequencies in colorectal adenomas and carcino-
mas, it was soon realized that the Wnt/β-catenin signaling pathway
plays an initiating and rate-limiting role in colorectal tumorigene-
sis (10–12). More recently, large-scale exome-sequencing efforts
have confirmed that Wnt/β-catenin signaling is deregulated in
more than 90% of all CRCs (13–15).
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Briefly, canonical Wnt signaling (i.e., Wnt/β-catenin signaling)
is initiated when Wnt proteins are released by stromal cells and
Paneth cells in the intestinal crypt, and these proteins bind to het-
erodimeric receptor complexes on the surface of intestinal stem
cells (Frizzled/Lrp6) and their immediate descendants (16). A
signal is then conveyed along a signaling cascade, which essen-
tially inhibits degradation of cytoplasmic β-catenin. β-Catenin
then soon translocates into the nucleus where it interacts with
DNA-bound TCF/Lef transcription factors, causing expression
of a range of genes related to proliferation and differentiation,
including SOX9. In cancer cells, mutations in APC, β-catenin, or
AXIN 2 cause constitutive activation of this signaling pathway,
leading to excess proliferation and inhibition of differentiation
of stem cell progenitors. Notably, β-catenin also serves another
essential cellular function in adherens junctions by linking E-
cadherin to the cytoskeleton, and recent evidence suggests that
this β-catenin pool is highly stable and unrelated to its impact on
Wnt signaling (16).
The prognostic potential of various components of the Wnt/β-
catenin pathway in CRC has been explored in many datasets
over the last decade, both on the genetic and the protein level.
In particular, deregulation of APC, β-catenin, and E-cadherin
has received much attention (17–19). From the very high fre-
quency of APC mutations in sporadic CRC, at around 70–
80% (20), it follows that its prognostic potential is likely lim-
ited. Indeed, few reports have documented robust clinical rele-
vance of this biomarker, neither at the genetic level (21) nor at
the protein level (22), although reports suggest that mutations
affecting β-catenin-binding sites may have prognostic value (13,
23). In contrast, the literature on β-catenin and E-cadherin has
been clouded by many conflicting findings due to a large num-
ber of unstandardized and underpowered studies (17, 18, 21,
24–38), and their potential as biomarkers in CRC still merits
further investigation.
SOX9 is a transcription factor and a downstream target of
Wnt/β-catenin signaling with possible roles in β-catenin reg-
ulation (39–42). Deregulation of SOX9 has been reported for
several cancers, including CRC (24), and recent large-scale exome-
sequencing efforts have revealed that SOX9 is mutated in a subset
of CRCs (15). The prognostic potential of SOX9 has only been
evaluated in one adequate CRC dataset, which suggested that high
expression of the SOX9 protein was associated with an adverse
prognosis (43).
Here, we used a tissue microarray (TMA) constructed from a
large consecutive, population-representative single-hospital series
of primary CRCs to explore the prognostic significance of
the protein expression of β-catenin, E-cadherin, and SOX9 by
immunohistochemistry. We have attempted to report the study
according to the REMARK guidelines (Table S1 in Supplemen-
tary Material) (44) and primarily focused on the clinical rel-
evance within CRC stages. We specifically sought to test the
hypotheses that (i) increased nuclear β-catenin staining is asso-
ciated with poor outcome, indicating active Wnt/β-catenin sig-
naling, that (ii) loss of β-catenin and E-cadherin membrane
staining is associated with poor outcome due to decoupling of
adherence junctions in epithelial–mesenchymal transition (EMT),
and whether (iii) differential expression of the downstream
Wnt signaling target, SOX9, identifies prognostic subgroups of
CRC patients.
MATERIALS AND METHODS
PATIENT MATERIAL
A population-representative consecutive series of 1290 CRC
patients admitted to Oslo University Hospital – Aker (1993–
2003) was analyzed. This hospital treated all CRC patients
from a geographically defined catchment area, including most
relapses. Of these, 929 patients underwent major resection,
and DNA was extracted from corresponding formalin-fixed
paraffin-embedded (FFPE) tissue from which a TMA was con-
structed (Figure 1). Major resection was defined as removal
of the tumor-bearing bowel segment with the lymphovascu-
lar pedicle and mesentery. All rectal cancers were surgically
removed by total mesorectal excision (TME). Resection sta-
tus was defined as R0 (complete resection/no residual tumor),
R1 (microscopic residual cancer at the resection margin), or
R2 (macroscopic or radiological evidence of residual cancer,
locally or distant). TNM-staging and histopathological grad-
ing followed the UICC/AJCC system, version 5. Comprehensive
clinical data had been prospectively registered on all patients
(Table 1). Microsatellite instability (MSI) status was previously
determined for all tumors (3) (Bruun et al., unpublished). More
than 95% of patients were of Caucasian ethnicity (based on
name-origin). Additional clinical information has been reported
elsewhere (3, 45).
The study was approved by the Regional Committee for Med-
ical and Health Research Ethics, South-Eastern Norway (REK
number 1.2005.1629) and the Norwegian Data Protection Author-
ity, and the patients were enrolled after informed consent. The
research conformed to the Declaration of Helsinki and the
research biobanks have been registered according to national
legislation.
IMMUNOHISTOCHEMICAL ANALYSES OF PROTEIN EXPRESSION ON
TMA
Cores from FFPE tissue from 670 colonic, 233 rectal, and 26 syn-
chronous carcinomas (one 0.6 mm diameter core per patient taken
from a viable, non-necrotic tumor area) from patients treated at
Oslo University Hospital – Aker (1993–2003), were organized into
a TMA according to the original method described by Kononen
and colleagues in 1998 (46).
The immunohistochemical analyses were done on 3–4µm
thick TMA sections on microscope slides, and were performed
as previously described (47). Briefly, sections were de-paraffinized
in xylene for 10 min, and then rehydrated. Antigen retrieval was
performed in a microwave oven by heating the sections in plas-
tic containers filled with Tris/EDTA-buffer (pH 9). Staining was
performed according to the DAKO Envision protocol, using the
reagents supplied with the K5007 kit (Dako, Glostrup, Den-
mark). Immunocomplexes were visualized with the chromogenic
stain diaminobenzidine (DAB). Hematoxylin staining was used
to visualize the nuclear compartment. A test TMA containing
representative tissues from nine human organs and six types
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FIGURE 1 | Flow diagram for inclusion of patients in the study. aTissue from four patients with endoscopic procedure included. bUnevaluable tissue had
insufficient number of epithelial tumor cells, extensive necrosis, and/or poor tumor preservation.
of cancer was utilized to optimize staining conditions to the
dynamic range of DAB by careful titration of antibodies. To eval-
uate non-specific secondary antibody reactions, a negative control
experiment was provided by omitting the primary antibody from
one slide.
For immunohistochemical analysis, mouse monoclonal anti-
β-catenin (Clone 14) antibodies were obtained from BD Bio-
sciences (San Jose, CA, USA; Catalog number 610154), recog-
nizing a C-terminal epitope between residue 571 and residue
781 of β-catenin. Mouse monoclonal anti-E-cadherin (Clone
36) antibodies were obtained from BD Biosciences (catalog
number 610181), recognizing a C-terminal epitope between
residue 735 and residue 883 of E-cadherin. Rabbit polyclonal
anti-SOX9 antibodies were obtained from Atlas antibodies AB
(catalog number HPA001758, Stockholm, Sweden), recogniz-
ing the 117 amino acid residue C-terminal end. The antibod-
ies were employed at dilutions of 1:800, 1:2000, and 1:500,
respectively.
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Table 1 | Patient characteristics for all patients included in the study.
Patient characteristic Frequency (n) Percentage (%)
Patients in the study 903 100
AGE
Median 73
Range 30–94
AGE (3 GROUPS, BINNED)
30–68 309 34.2
69–77 292 32.3
78–94 302 33.4
GENDER
Male 429 47.5
Female 474 52.5
STAGE
I 133 14.8
II 363 40.4
III 237 26.4
IV 165 18.4
ND 4 –
HISTOPATHOLOGIC GRADE
G1 84 9.6
G2 674 76.8
G3 108 12.3
Mucinousa 12 1.4
NDa 25 –
TUMOR LOCATION
Proximal colon 367 40.6
Distal colon 302 33.4
Rectum 234 25.9
RESECTION
0 713 79.0
1 19 2.0
2 170 18.8
NDa 1 –
MICROSATELLITE INSTABILITY
MSI 119 14.5
MSS 700 85.5
NDa 84 –
aExcluded from statistical analyses. ND, no data.
EVALUATION OF IMMUNOSTAINING
The staining of β-catenin, E-cadherin, and SOX9 was scored
according to the proportion and intensity categories proposed
by Allred et al. (48). The proportion score represents the esti-
mated fraction of positive cells (0= none, 1=<1%, 2= 1–10%,
3= 11–33%, 4= 34–66%, and 5= 67–100%), while the inten-
sity score represents their average staining intensity (0= negative,
1=weak, 2= intermediate, and 3= strong). The final Allred-
score for each tumor is calculated by adding these two scores.
Staining was evaluated and scored separately for membranous,
cytoplasmic, and nuclear staining patterns. The scores were com-
bined into strong, moderate, and weak categories. The cate-
gories were determined by the number of patients and events
in each subgroup, and the ability to visually differentiate reliably
between the staining scores. All analyses were done in paral-
lel on ungrouped scores demanding that findings were valid
for both ungrouped and grouped data. The scoring was per-
formed independently by two investigators (Jarle Bruun and
Matthias Kolberg), blinded to clinical data, in close collab-
oration with an experienced pathologist (Jahn M. Nesland).
All discrepancies were resolved and reassigned on consensus
of opinion.
For β-catenin the interobserver agreement, as measured by
the intraclass correlation coefficients (ICC) (49) were 0.88, 0.89,
and 0.85 for membranous, cytosolic, and nuclear staining, respec-
tively; for E-cadherin 0.84 and 0.67 for membranous and cytoso-
lic staining, respectively; for SOX9 0.93 for nuclear staining.
Due to the limited ability of the Allred scoring system to dif-
ferentiate proportionately between negative tumors (score 0)
and weak tumors (score 4–6, mostly), these ICCs underestimate
the true ICC value, especially for cytosolic staining for which
tumors largely exhibited a uniform staining with proportion
scores of 4 or 5. Calculations were confirmed by cross-tabular
visualizations.
STATISTICAL ANALYSES
Five-year overall survival (OS) and time-to-recurrence (TTR)
plots were generated using the Kaplan–Meier method in the
SPSS 18.0 software (SPSS, IL, USA). TTR and OS were defined
according to the guidelines given by Punt et al. (50). Briefly,
TTR was defined as the time from surgery to the first event of
either death from the same cancer, local recurrence, or distant
metastasis. Patients were censored at death from other cancer,
non-cancer death, post-operative death (<3 months), and loss
to follow-up. OS was defined as the time from surgery to death
from any cause, and patients were censored at loss to follow-
up. No patients were lost to follow-up in the study period. The
logrank test for trend was used to compare survival between
ordinal groups, and Cox proportional hazards regression mod-
eling (Wald test) was used to provide univariate and multivari-
ate hazard-ratios (HR) and confidence intervals (CI). Age cat-
egories were created by three-tire binning to achieve sufficient
statistical strength within each category. In multivariate analy-
ses, the protein parameters with significant independent impact
on patient survival were adjusted for the standard and high-
risk clinicopathological variables: age, gender, tumor stage, tumor
differentiation, tumor location, MSI status, and residual tumor
status. Adjuvant treatment for patients with stage III colon can-
cer (<75 years of age) became standard treatment in 1997 and
was considered in initial multivariate models. These patients
were few and adjustment did not affect the models. Adjust-
ment for pre- and post-operative radiotherapy for rectal cancer
patients was also considered, but was pertinent to only a very
limited number of patients and therefore not included in initial
models. The proportional hazards assumptions were verified by
graphical evaluation of plots of log (−log survival time) versus
log time.
The correlation and survival analyses involve multiple tests
and false positive findings are to be expected with a 5% signifi-
cance level. However, several of the clinicopathological parame-
ters, such as stage and differentiation, can be assumed to have
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some a priori association with the three biomarkers, reducing
the need for rigorous correction. Clinically relevant subgroup
analyses were therefore pre-specified and additional subgroup
analyses labeled as exploratory. Interaction tests were integrated
in the Cox models to assess whether effects were different between
subgroups, but must be interpreted carefully due to the low
power of such tests. All P-values were two-sided and derived
from statistical tests using SPSS, and considered statistically sig-
nificant at P < 0.05. To correct for multiple testing in the cor-
relation analyses, we set a significance threshold of P < 0.001.
Correlation between expression of protein markers and stan-
dard clinicopathological variables was evaluated using Spearman’s
rho test.
RESULTS
TMA IMMUNOSTAINING RESULTS
Among 903 stained histospots, 722 (80%) were evaluable for β-
catenin, 720 (80%) for E-cadherin, and 761 (84%) for SOX9
(Figure 2). The rest of the histospots were unevaluable due to
insufficient number of epithelial tumor cells, extensive necro-
sis, poor tumor preservation, or loss of tissue on the TMA
slide. Eighty-five samples with very strong cytoplasmic β-catenin
staining could not be evaluated for nuclear staining, leaving 637
(71%) for this purpose. No bias of clinical data was observed for
these 85 samples. Generally, the tumor exhibited various degrees of
staining for all the three proteins in the compartments investigated
(Figure S1 in Supplementary Material).
CORRELATION BETWEEN IMMUNOSTAINING ANDWITH
CLINICOPATHOLOGICAL VARIABLES
Membrane and cytosolic β-catenin staining correlated strongly
with E-cadherin staining, in accordance with their common func-
tional roles in adherens junctions (Table 2). Nuclear β-catenin,
however, correlated only with cytosolic β-catenin, but not to
β-catenin membrane staining, E-cadherin, or SOX9.
All the tested biomarkers in all subcellular locations were more
highly expressed in MSS tumors than in MSI, except for β-catenin
membrane and nuclear SOX9 staining, but these showed the same
trend (Table 3). Similar, but weaker associations were found for
left-sided tumors (including rectum) as compared to right-sided
tumors (Table 3). Histopathologic grade was also positively corre-
lated with expression of all biomarkers. The correlation was weaker
for β-catenin membrane and nuclear staining, and SOX9 nuclear
staining, but these showed the same trend.
FIGURE 2 | Representative immunostaining patterns for P-catenin, E-cadherin, and SOX9 (core diameter 0.6mm).
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Table 2 | Correlation between staining of studied biomarkers.
Marker β-Catenin (P, r, n) E-cadherin (P, r, n) SOX9 (P, r, n)
Cytosol Membrane Nucleus Cytosol Membrane Cytosol Nucleus
β-CATENIN
Cytosol 1 6.6×10−25 1.2×10−49 9.7×10−26 5.3×10−22 2.0×10−10 1.3×10−5
0.37 0.54 0.38 0.35 0.24 0.16
722 637 702 702 700 700
Membrane 1 0.0079 3.0×10−32 2.5×10−63 0.36 0.22
−0.11 0.43 0.58 0.034 0.046
637 702 702 702 702
Nucleus 1 0.17 0.011 0.17 0.037
0.055 0.1 0.055 0.084
618 618 616 616
E-CADHERIN
Cytosol 1 3.1×10−86 0.57 0.42
0.65 0.022 −0.03
720 694 694
Membrane 1 0.48 0.064
0.027 0.07
694 694
SOX9
Cytosol 1 3.1×10−70
0.58
761
Nucleus 1
P-values and correlation coefficients (r) from Spearman’s rho test. The correlations are calculated using ungrouped Allred staining scores.
There were no significant correlations with any of the clinical
parameters age, gender, or tumor stage.
SURVIVAL ANALYSIS
Univariate and multivariate OS analysis of all patients and TTR
analysis of patients with complete resection were carried out
in order to assess the prognostic potential of each of the three
biomarkers.
LOSS OF β-CATENIN INDEPENDENTLY PREDICTS POOR OUTCOME
Univariate analyses showed that decreased membranous staining
of β-catenin was significantly associated with a worse prognosis
(Figure 3; Tables 4 and 5).
A multivariate Cox regression model including standard clin-
icopathological variables demonstrated that β-catenin membra-
nous staining was an independent prognostic marker using OS as
an endpoint (Table 4), but not using TTR as an endpoint (Table 5).
Stratification according to stage demonstrated valid signifi-
cance for OS only within stage IV (P = 3.7× 10−7, n= 134 with
125 events, Table 6), supported by formal interaction tests (inte-
grated in the Cox-model) assessing the probability of subgroup
effects (P = 0.018 for β-catenin and P = 0.025 for the inter-
action test between β-catenin and stage). Further exploratory
subgroup analyses of β-catenin membrane staining by standard
clinicopathological variables showed that the initial association
to survival was also particularly significant for females (OS,
Females, P = 5.2× 10−4, n= 380; Males, P = 0.18, n= 342; TTR,
Females, P = 0.047, n= 292; Males, P = 0.78, n= 276). However,
interaction tests were not significant.
Decreased cytosolic β-catenin staining was significantly asso-
ciated with a worse prognosis in both OS (Table 4) and TTR
univariate analyses (Figure 3; Table 5).
Multivariate analysis (OS) demonstrated that cytosolic β-
catenin expression was an independent prognostic marker
(Table 4). Multivariate TTR analysis exhibited a similar trend,
but was not statistically significant at the conventional 5% level
(Table 5).
Exploratory subgroup analyses (OS) showed a particular age-
related effect for younger patients (<69 years of age, P = 0.0010,
n= 246; 69–77 years of age, P = 0.62, n= 227, 78–96 years of
age, P = 0.26, n= 249). This finding was supported by signifi-
cant interaction tests (P = 0.0025 for β-catenin and P = 0.038 for
the interaction test). The strata had unfortunately too few patients
and events to perform an adequate TTR analysis.
Nuclear β-catenin staining was not associated with progno-
sis alone or stratified according to standard clinicopathological
variables (Figure 3; Tables 4 and 5).
LOSS OF E-CADHERIN INDEPENDENTLY PREDICTS POOR OUTCOME
In univariate analyses, there was no significant association between
membranous E-cadherin staining and prognosis, but the KM-
plots and logrank tests suggest that loss of membranous E-
cadherin is associated with a worse prognosis (Figure 4; Tables 4
and 5).
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Table 3 | Correlation between studied biomarkers and patient characteristics.
Patient characteristic β-Catenin (P, r, n) E-cadherin (P, r, n) SOX9 (P, r, n)
Cytosol Membrane Nucleus Cytosol Membrane Cytosol Nucleus
Age 0.60–0.020 0.83 0.81 0.45 0.57 0.097 0.033
722 0.0078 0.01 −0.028 0.021 0.06 0.077
722 637 720 720 761 761
GENDER
Female=1 Male=2 0.036 0.4 0.025 0.072 0.028 0.85 0.43
0.078 0.031 0.089 0.067 0.082 −0.0069 −0.029
722 722 637 720 720 761 761
Stage 0.081 0.043 0.3 0.013 0.088 0.035 0.74
−0.065 −0.076 0.041 −0.093 −0.064 −0.077 −0.012
718 718 633 716 716 757 757
HISTOPATHOLOGIC GRADE
G1, G2, G3 2.4×10−6 0.014 0.14 8.0×10−6 2.9×10−5 7.1×10−5 0.057
0.18 0.093 0.059 0.17 0.16 0.15 0.07
694 694 612 691 691 731 731
TUMOR LOCATION
Right=1 2.8×10−9 0.17 1.2×10−6 3.8×10−7 2.2×10−6 0.13 0.11
Left=2 0.22 0.051 0.19 0.19 0.18 0.055 −0.059
Rectum=3 722 722 637 720 720 761 761
RESECTION
R0, R1, R2 0.028 0.2 0.48 0.045 0.35 0.027 0.93
−0.082 −0.047 0.028 −0.075 −0.035 −0.08 −0.0032
721 721 636 719 719 760 760
MSI status 3.6×10−21 0.012 1.1×10−12 2.6×10−9 1.5×10−9 1.8×10−6 0.091
MSI=1 0.36 0.097 0.29 0.23 0.23 0.18 0.064
MSS=2 661 661 584 657 657 693 693
P-values and correlation coefficients (r) from Spearman’s rho test. Correlations are calculated using ungrouped Allred staining scores.
However, there was a significant association between loss of
cytosolic E-cadherin and a worse prognosis, both employing OS
(Table 4) and TTR (Table 5) as an endpoint (Figure 4).
When standard clinicopathological variables were adjusted for
by Cox modeling, cytosolic E-cadherin staining was still an inde-
pendent prognostic biomarker in TTR analysis (Table 5), but
not in OS analysis (Table 4). Stratification by stage suggested
that the effect was limited to stage II [P = 0.046, n= 299 with
111 events (OS) and P = 0.033, n= 279 with 74 events (TTR)
(Table 6)]. However, interaction tests were not significant. Further
exploratory subgroup analyses did not pinpoint other effects.
SOX9 IS NOT ASSOCIATED WITH PROGNOSIS
Neither nuclear nor cytosolic staining of SOX9 protein was
associated with prognosis, neither unstratified nor stratified on
subgroups (Figure 5; Tables 4 and 5).
DISCUSSION
In the present study, we took advantage of the high-throughput
capabilities of the TMA technology to evaluate the prognostic
value of β-catenin, E-cadherin, and SOX9 protein expression in
a large consecutive population-representative series of primary
CRCs. We found that loss of β-catenin or E-cadherin protein
expression in tumors was associated with worse disease outcome.
This result fits well with a large body of evidence which demon-
strates that β-catenin and E-cadherin are often down-regulated in
cancer (17, 18, 51–54), reflecting the invasive properties of can-
cer cells and follows logically from a malignant cancer cell’s need
to detach from neighboring cells through decoupling of adherens
junctions and activation of Wnt/β-catenin signaling in order to
invade neighboring tissue (55). SOX9, on the other hand, was
shown to not carry any prognostic information.
In normal colonic epithelia, both β-catenin and E-cadherin are
predominantly expressed at the cell membrane (22, 25, 26, 56, 57),
and many previous studies have analyzed the prognostic value
of their altered expression in tumors, but the reported results
are highly divergent (18, 19). While some studies have reported
worse outcome for patients with low expression of β-catenin in the
nucleus and other compartments (27–30), others have reported no
difference in prognosis (26, 31, 43), and yet others have found that
strong expression is associated with poor outcome (22, 32–34).
The literature on E-cadherin is also marked by conflicting results,
where some groups have reported no prognostic effect of altered
E-cadherin expression (35, 36), whereas others have reported that
patients with low E-cadherin expression have a poor prognosis
(37, 38, 58).
Likely reasons for these discrepant results may be that the large
majority of the published studies were carried out retrospectively
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FIGURE 3 |Weak staining of β-catenin predicts poor outcome.
in small series with different patient inclusion criteria, and the ana-
lytical approaches employed vary greatly, particularly in reference
to clinical endpoints, primary antibodies, immunohistochemical
scoring systems, cutoff thresholds, and reporting of statistical
methodology. The selection, quality, and representativeness of a
patient series may also bias the results.
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Table 4 | Univariate and multivariate modeling by Cox regression (Wald test), overall survival (OS).
Variable Univariate Multivariate
Pa HR 95% P n Events HR 95% CI P n Events
Ageb – 1.027 1.019–1.036 5.35×10−10 903 449 1.036 1.027–1.046 2.0×10−13
GENDER
Female 1 1
Male 0.4 0.92 0.77–1.11 0.4 903 449 1.1 0.88–1.33 0.48
STAGE
I 1 1
II 1.89 1.27–2.80 1.61 1.05–2.46
III 3.06 2.06–4.57 2.83 1.85–4.33
IV 1.6×10−56 11.5 7.77–17.2 1.7×10−63 898 446 3.91 2.22–6.89 1.6×10−8
HISTOPATHOLOGIC GRADE
G1 1 1
G2 1.49 1.03–2.16 1.21 0.81–1.80
G3 1.6×10−7 2.8 1.84–4.27 2.0×10−7 866 433 2.33 1.46–3.71 1.3×10−5
TUMOR LOCATION
Proximal colon 1 1
Distal colon 1.01 0.82–1.25 0.95 0.75–1.21
Rectum 0.0061 0.69 0.54–0.88 0.0048 903 449 0.9 0.068–1.20 0.76
RESECTION
0 1 1
1 2.03 1.11–3.71 1.7 0.84–3.45
2 6.2×10−85 6.17 5.03–7.56 2.88×10−67 902 448 3.47 2.31–5.21 8.4×10−9
MICROSATELITE STATUS
MSI 1 1
MSS 0.039 1.37 1.01–1.84 0.04 819 412 1.69 1.18–2.42 0.0043 787 396
β-CATENIN MEMBRANE STAININGc
Weak 1 1
Moderate 0.64 0.48–0.85 0.61 0.45–0.83
Strong 2.6×10−4 0.41 0.23–0.71 0.0012 722 361 0.54 0.29–0.99 0.0065 637 321
β-CATENIN CYTOSOLIC STAININGc
Weak 1 1
Moderate 0.61 0.42–0.89 0.6 0.40–0.89
Strong 0.005 0.56 0.40–0.79 0.0038 722 361 0.64 0.44–0.93 0.033 637 321
β-CATENIN NUCLEAR STAININGc
Weak 1 1
Moderate 1.09 0.85–1.40 0.99 0.75–1.30
Strong 0.43 1.11 0.83–1.48 0.7 637 319 0.97 0.71–1.34 0.99 562 282
E-CADHERIN MEMBRANE STAININGc
Weak 1 1
Moderate 0.97 0.70–1.36 0.93 0.63–1.36
Strong 0.1 0.82 0.60–1.12 0.23 720 355 0.79 0.54–1.15 0.3 633 315
E-CADHERIN CYTOSOLIC STAININGc
Weak 1 1
Moderate 0.8 0.64–0.99 0.93 0.73–1.18
Strong 0.0014 0.69 0.48–1.00 0.045 720 355 0.85 0.57–1.28 0.69 633 315
SOX9 CYTOSOLIC STAININGc
Weak 1 1
Moderate 0.87 0.70–1.08 1.06 0.83–1.34
Strong 0.5 0.99 0.70–1.39 0.4 761 383 1.04 0.72–1.51 0.89 668 339
(Continued)
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Table 4 | Continued
Variable Univariate Multivariate
Pa HR 95% P n Events HR 95% CI P n Events
SOX9 NUCLEAR STAININGc
Weak 1 1
Moderate 0.98 0.76–1.27 1.13 0.85–1.50
Strong 0.82 1.03 0.77–1.36 0.93 761 383 0.99 0.72–1.36 0.53 668 339
aLogrank test.
bAge is implemented as a continuous variable.
cAdjusted for age, gender, stage, grade, location, resection, and microsatellite status.
The patients in the present study were consecutively enrolled
from a geographically defined catchment area, and all relevant
clinical data were prospectively registered. Repeated quality con-
trols have been performed for the hospital records to ensure high
quality of these data. Furthermore, completeness of the series was
verified against the Cancer Registry of Norway where all cancer
diagnoses in Norway are recorded. Hence, the series can be con-
sidered to be population-representative and of a size that allows
for stratification and subgroup analyses.
Recently, a meta-analysis assessed the prognostic significance of
β-catenin protein expression in CRC and concluded that nuclear
expression was significantly associated with a poor prognosis,
while cytoplasmic expression was not associated to prognosis
(59). However, when we repeated the meta-analysis using their
input data, we found a significant publication bias, and when we
adjusted for this using a trim-and-fill approach (60), we found
that there was no prognostic effect of nuclear β-catenin expres-
sion (Figure S2 in Supplementary Material), which is in agreement
with our finding. Furthermore, two other large studies that did
not find any effect of nuclear β-catenin were not included in the
meta-analysis (22, 30). An overview of all the main findings in
studies having sample sizes above 200 is summarized in Table S1
in Supplementary Material.
Even though the corrected meta-analysis suggests that there
is no prognostic value in assessing nuclear β-catenin expression,
one cannot exclude an undefined functional and prognostic rela-
tionship among membranous, cytosolic, and nuclear β-catenin
protein expression. Furthermore, the phosphorylation status of β-
catenin has also been shown to carry prognostic information (26).
More quantitative tools are needed to determine these relation-
ships exactly. It may also be functionally relevant to investigate
the expression of β-catenin at the tumor invasion front where
it has been shown to play an important role in the process of
EMT (55, 61–63).
Potential benefit from combining the markers β-catenin, E-
cadherin, and SOX9 was explored, but this did not improve strat-
ification of patients, likely due to the high correlation between
β-catenin and E-cadherin and the lack of prognostic information
carried by SOX9.
Notably, we found that MSI tumors exhibit a significantly
lower expression of β-catenin, E-cadherin, and SOX9 protein than
MSS tumors. Similarly, right-sided tumors showed lower protein
expression compared to left-sided and rectal tumors, although this
is likely dependent on the higher level of MSI tumors on the right
side. Similar correlations have been reported by other groups (22,
30, 31, 64, 65). The low expression of β-catenin, E-cadherin, and
SOX9 in MSI tumors suggests that the Wnt/β-catenin pathway may
be less important in these tumors. On the other hand, both MSI
and MSS tumors are dependent on active Wnt/β-catenin signal-
ing. Recent studies have suggested that tumorigenic Wnt/β-catenin
signaling may be subject to dose- and tissue-dependent regulation
through the existence of different APC genotypes in right- and left-
sided tumors (66). APC-mutations reflecting differential inactiva-
tion have been documented in independent tumor series (67–69),
supporting the “just-right”-hypothesis that different thresholds
exist for optimal tumorigenic Wnt/β-catenin signaling (66, 70),
which may explain the observed differences in staining between
MSI and MSS tumors. Moreover, it has been reported that small
absolute changes (but rather relevant fold-changes) in β-catenin
levels may have significant effect on Wnt/β-catenin signaling (71).
Hence, a lower expression of these proteins may not necessarily
indicate that the functional effects are different from in tumors
with a higher absolute protein expression.
There was also a positive correlation between the three bio-
markers and the histopathologic grade of the tumor. This is
in accordance with the assumption that tumors with lower dif-
ferentiation grade have a more mesenchymal phenotype with
down-regulated levels of adherens junctions and presumably lower
activity of particular components of the Wnt/β-catenin signal-
ing pathway. We also note that the nuclear staining of SOX9
does not correlate significantly to MSI and histopathologic grade,
which may suggest different biological roles for SOX9 in these two
compartments.
In our dataset, SOX9 did not carry any prognostic information
contrasting with the finding by Lü et al., which reported that strong
SOX9 protein expression was an independent adverse prognostic
biomarker in a Chinese patient population of 188 primary CRCs
with complete resection (43). Selection bias and preanalytical vari-
ability may partly explain the lack of accordance as their samples
were retrieved from three different hospitals and also constitute a
considerably smaller series in total. Significant population effects
may also exist due to genetic differences between populations.
Limitations to our study are primarily related to the
previously mentioned shortcomings of protein analyses by
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Table 5 | Univariate and multivariate modeling by Cox regression (Wald test), time to recurrence (TTR).
Variable Univariate Multivariatea
Pa HR 95% P n Events HR 95% CI P n Events
Ageb – 1.017 1.005–1.029 0.0067 693 206 1.023 1.009–1.037 9.4×10−4
GENDER
Female 1 1
Male 0.96 1.007 0.77–1.32 0.96 693 206 1.09 0.80–1.47 0.6
STAGE
I 1 1
II 2.68 1.55–4.63 2.38 1.35–4.18
III 4.97 2.88–8.58 4.75 2.72–8.30
IV 2.3×10−45 9.56 4.29–21.3 5.1×10−11 689 205 8.02 3.5–18.2 3.1×10−10
HISTOPATHOLOGIC GRADE
G1 1 1
G2 1.34 0.81–2.21 1.14 0.68–1.93
G3 2.47 1.37–4.47 0.0024 666 200 2.29 1.21–4.31 0.0042
TUMOR LOCATION
Proximal colon 1 1
Distal colon 1.02 0.74–1.41 0.99 0.68–1.43
Rectum 0.82 1.04 0.74–1.45 0.98 693 206 1.27 0.86–1.88 0.37
MICROSATELITE STATUS
MSI 1 1
MSS 0.2 1.31 0.86–1.97 0.21 627 194 1.63 0.99–2.71 0.057 603 187
β-CATENIN MEMBRANE STAININGc
Weak 1 1
Moderate 0.72 0.45–1.14 0.84 0.50–1.41
Strong 0.052 0.47 0.21–1.05 0.16 553 163 0.68 0.29–1.60 0.67 489 149
β-CATENIN CYTOSOLIC STAININGc
Weak 1 1
Moderate 0.88 0.49–1.56 0.72 0.39–1.35
Strong 0.013 0.61 0.35–1.05 0.043 553 163 0.55 0.30–1.01 0.1 489 149
β-CATENIN NUCLEAR STAININGc
Weak 1 1
Moderate 0.99 0.69–1.43 0.91 0.61–1.36
Strong 0.63 0.89 0.56–1.39 0.86 485 142 0.86 0.53–1.41 0.82 429 129
E-CATENIN MEMBRANE STAININGc
Weak 1 1
Moderate 1.11 0.68–1.81 0.93 0.53–1.65
Strong 0.1 0.79 0.49–1.26 0.12 555 164 0.79 0.45–1.39 0.55 489 150
E-CATENIN CYTOSOLIC STAININGc
Weak 1 1
Moderate 0.65 0.47–0.89 0.67 0.47–0.95
Strong 9.3×10−4 0.46 0.26–0.83 0.004 555 164 0.48 0.25–0.92 0.02 489 150
SOX9 CYTOSOLIC STAININGc
Weak 1 1
Moderate 0.9 0.65–1.24 1.04 0.72–1.49
Strong 0.87 1.05 0.63–1.75 0.74 583 168 1.09 0.63–1.90 0.95 512 153
SOX9 NUCLEAR STAININGc
Weak 1 1
Moderate 1.06 0.72–1.55 1.03 0.68–1.56
Strong 0.52 0.88 0.56–1.37 0.61 583 168 0.79 0.48–1.29 0.41 512 153
aLogrank test.
bAge is implemented as a continuous variable.
cAdjusted for age, gender, stage, grade, location, and microsatellite status.
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Table 6 | Univariate and multivariate modeling of subgroup analyses by Cox regression (Wald test).
Variable Univariate Multivariatea
Pa HR 95% P n Events HR 95% CI P n Events
β-CATENIN MEMBRANE STAININGb
Weak 1 1
Moderate 8.6 2.86–25.8 3.2 0.97–10.5
Strong 3.7×10−7 2 0.73–5.41 5.7×10−8 134 125 0.92 0.32–2.67 6.7×10−5 120 112
E-CADHERIN CYTOSOLIC STAININGc
Weak 1 1
Moderate 0.63 0.39–1.03 0.55 0.32–0.93
Strong 0.033 0.51 0.21–1.19 0.091 273 74 0.36 0.14–0.94 0.024 239 64
aLogrank test for trend.
bSubgroup analysis for tumor stage IV using overall survival as endpoint, adjusted for age, gender, grade, location, resection, and microsatellite status.
cSubgroup analysis for tumor stage II using time to recurrence as endpoint, adjusted for age, gender, grade, location, and microsatellite status.
FIGURE 4 |Weak staining of E-cadherin predicts poor outcome.
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FIGURE 5 | SOX9 does not predict disease outcome.
immunohistochemistry being subject to preanalytical variability,
tumor heterogeneity, and subjective scoring systems limiting its
reproducibility. The two former are to a certain degree compen-
sated for by using a large sample series, while the latter can only be
assessed properly by independent validations. We are also aware
that stage migration, due to more patients being classified to higher
stages while diagnostic methods have become more sensitive, may
bias our assessments of stage specific survival (45).
TNM-stage classification is well-established to assess CRC
prognosis. Survival varies considerably between stages, at about
90% for localized disease compared to about 10% for metasta-
tic disease (72), although prognosis may vary significantly within
stages. Adjuvant chemotherapy is offered as standard treatment
to high-risk stage II patients and stage III patients below 75 years
of age. However, up to one-third of stage II patients relapse (3)
and elderly patients seem to benefit from adjuvant therapy (4, 5),
justifying a need for prognostic biomarkers that can identify high-
and low-risk patients in these subgroups. Recently, MSI was intro-
duced into clinical guidelines as a marker for improved prognosis
that also likely predicts lack of response to 5-FU monotherapy
(73) (www.nccn.org). In our study, strong versus weak β-catenin
membrane expression showed the clearest stratification of patients
into poor and good prognostic groups (Table 4). Unfortunately,
subgroup analysis by stage demonstrated that this effect was evi-
dent neither in stage II nor in stage III, but rather in stage IV,
suggesting that stage IV patients with low β-catenin membrane
expression may benefit from a more or less intensive treatment
depending on their health condition. Cytosolic E-cadherin on the
other hand, might have some prognostic value for stratification of
stage II patients. Independent validations are warranted to con-
firm these results. If validated, we believeβ-catenin and E-cadherin
may serve as valuable biomarkers in a panel of biomarkers. They
are not likely to separate high- and low-risk patient groups with
sufficient precision for a clinical test as sole biomarkers.
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In summary, nuclear β-catenin protein expression lacks prog-
nostic value for CRC, while decreased expression of both membra-
nous and cytosolic E-cadherin and β-catenin are associated with
worse outcome among primary CRC patients, having potential to
serve as biomarkers in stage II and IV CRC, respectively.
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